Akums Drugs & Pharmaceuticals Ltd Share Price

Pharmaceuticals

NSE: AKUMS Small Cap ISIN: INE09XN01023

As on 16 May 2025 at 19:58 IST

₹ 515

+ 2.80

(0.55%)

Sell Buy

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd. was founded in the year 2004. Headquartered in Delhi, India, it has rapidly established itself as a prominent player in the pharmaceutical industry. The company has carved out a niche as a leading Contract Development and Manufacturing Organization (CDMO). Akum’s diverse portfolio allows it to cater to a wide array of healthcare needs and market demands. Its expertise spans various dosage forms, including oral solids, injectables, cosmetics and nutraceuticals. Akums’ success is mainly seen through its commitment to providing customized solutions that meet global standards. +

Over 1 Month

21.55%

Over 6 Months

-36.17%

Over 1 Year

-35.67%

Over 3 Years

None%

Akums Drugs & Pharmaceuticals Ltd Summary

Close ₹512.20

Open ₹498

High ₹515.35

Low ₹498

Volume 1,39,537

Net Turnover (in Cr) ₹7.09

52Wk High ₹1,175.90

52Wk Low ₹405

52Wk High / Low

405

1,175.90

Akums Drugs & Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹8,061.72

EPS (TTM) 4.87

Book Value (BV) 142.04

Div. Yield -

P/E (TTM) 106.89

Price/Book Value 3.61

Delivery % 36.73 %

Face Value 2

Key Ratios

PE Ratio -

PB Ratio -

EV to Sales -

PEG Ratio -

ROA -9.22

ROE -69.32

Debt-Equity 0.82

Net Profit Margin -10.93

Operating Profit Margin -2.25

Akums Drugs & Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	4,212.21	3,744.89	3,694.52	2,743.79	2,441.64
Total Expenses	4,231.45	3,519.89	3,874.95	2,561.87	2,326.66
Profit Before Tax	-45.28	150.30	-193.20	172.26	113.82
Profit After Tax	0.79	97.82	-250.87	123.44	43.65
Operating Profit After Depreciation	31.37	271.25	-163.77	188.66	134.92

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	1,191.05	1,097.47	1,020.79	833.80	644.38
Total Non Current Assets	1,575.58	1,387.65	1,204.98	1,034.61	828.42
Total Current Assets	1,940.78	1,878.87	1,864.06	1,157.40	1,249.85
Total Assets	3,516.36	3,266.53	3,069.05	2,192.02	2,078.27
Total Shareholder's Fund	709.50	717.19	621.98	884.85	722.40

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	498.26	176.63	31.85	134.89	28.13
Net Cash Used In Investing Activities	-330.80	-304.70	-234.82	-109.38	-189.87
Net Cash Used In Financing Activities	-108.02	124.54	236.04	-95.22	233.01

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,538.24	1,382.98	1,220.54	891.95	802.43
Total Expenses	1,621.78	1,088.13	1,555.51	837.65	726.58
Profit Before Tax	-102.93	150.32	-334.98	-195.20	75.85
Profit After Tax	-165.45	125.43	-381.77	-145.43	50.86
Operating Profit After Depreciation	-65.23	308.03	-331.32	55.11	80.19

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	298.57	253.27	233.50	229.09	225.84
Total Non Current Assets	1,562.29	1,373.12	1,258.79	916.94	932.13
Total Current Assets	533.14	521.08	555.16	381.41	494.14
Total Assets	2,095.43	1,894.21	1,813.95	1,298.35	1,426.26
Total Shareholder's Fund	143.88	311.50	185.54	567.05	712.32

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	247.91	94.01	228.31	55.57	-21.75
Net Cash Used In Investing Activities	-165.44	-202.17	-297.96	-99.96	-241.71
Net Cash Used In Financing Activities	-20.74	89.90	94.99	2.60	301.53

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	1,010.41	1,033.09	1,019.11	944.21	1,082.84
Total Expenses	889.05	911.90	891.10	941.22	989.40
Profit Before Tax	91.05	91.59	87.48	-32.88	59.29
Profit After Tax	66.31	66.65	61.21	-39.47	195
Operating Profit after Depreciation	135.92	134.66	134.56	13.23	102.36

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	337.41	328.35	317.28	298.35	383.15
Total Expenses	303.38	285.28	273.59	358.88	351.44
Profit Before Tax	54.90	61.62	54.28	-49.05	43.45
Profit After Tax	41.17	50.37	41.88	-57.87	29.34
Operating Profit after Depreciation	67.87	75.19	69.87	-33.87	56.60

Akums Drugs & Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 501.68

S2 491.17

S3 484.33

Pivot 508.52

R1 519.03

R2 525.87

R3 536.38

Moving Average

20 SMA 492.42

50 SMA 491.55

100 SMA 541.58

200 SMA -

Akums Drugs & Pharmaceuticals Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

Akums Drugs & Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,781.35	₹4,27,405.53
Divis Laboratories Ltd	₹6,144.35	₹1,63,113.19
Cipla Ltd	₹1,508.95	₹1,21,868.90
Torrent Pharmaceuticals Ltd	₹3,289.90	₹1,11,340.16
Mankind Pharma Ltd	₹2,430.05	₹1,00,258.65

Akums Drugs & Pharmaceuticals Ltd Top Mutal Funds Invested

Fund Name	AUM
Franklin India Opportunities Fund	1.52%
Templeton India Value Fund	1.37%
PGIM India Small Cap Fund	1.11%
SBI Healthcare Opportunities Fund	1.09%
Franklin India Smaller Companies Fund	0.88%

Akums Drugs & Pharmaceuticals Ltd News

Akums Drugs & Pharmaceuticals to table results

On 6 February 2025

01 Feb 2025, 05:13 pm

Akums Drugs drops as IT dept conducts search at its offices & units

Akums Drugs and Pharmaceuticals slumped 4.99% to Rs 594.95 after the Income Tax Department conducted search at the firm's offices and manufacturing units.

22 Jan 2025, 12:07 pm

Akums Drugs rallies on inking pact to supply pharmaceutical formulations in Europe

Akums Drugs and Pharmaceuticals gained 3.04% to Rs 616.10 after it entered into an agreement with one of leading global pharma company for manufacture and supply of selected pharmaceutical formulations in European Market.

24 Dec 2024, 01:01 pm

Akums Drugs ties up with Jagdale Inds for marketing of ready-to-drink nutritional beverages

Akums Drugs and Pharmaceuticals said that its wholly owned subsidiary Maxcure Nutravedics has entered into a collaboration agreement with Jagdale Industries for marketing of ready-to-drink nutritional beverages.

26 Nov 2024, 12:47 pm

Akums Drugs hits life high on inking pact with Caregen

Akums Drugs and Pharmaceuticals was locked in upper circuit of 5% at Rs 580.95 after the company entered into an exclusive master sales agreement with Caregen, a South Korean company in the nutraceuticals segment, to sell Caregen's range in India.

19 Nov 2024, 12:59 pm

Akums Drugs & Pharmaceuticals Ltd Stock Analysis

Annual revenue for Akums Drugs & Pharmaceuticals Ltd increased by 11.23% to ₹1,538.24 crore in FY 2024 from ₹1,382.98 crore in FY 2023.
Annual Net Profit for Akums Drugs & Pharmaceuticals Ltd decreased by 231.91% to ₹-165.45 crore in FY 2024 from ₹125.43 crore in FY 2023.
Promoter Shareholding in Akums Drugs & Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 75.26% in December 2024 to 75.26% in March 2025.
Akums Drugs & Pharmaceuticals Ltd delivered a 1-year return of -35.67% compared to the Nifty 50, which provided a return of 9.47% as of the last trading session.
Akums Drugs & Pharmaceuticals Ltd share price moved up by 0.55% from its previous close of INR ₹512.20. The latest Akums Drugs & Pharmaceuticals Ltd share price is INR ₹515.
Akums Drugs & Pharmaceuticals Ltd share price today has been at a low of 510.60 and a high of 527.95. Over the past 52 weeks, the Akums Drugs & Pharmaceuticals Ltd share price has seen a low of 405 and a high of 1,175.90.

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd., founded in 2004 and headquartered in Delhi, India, has rapidly established itself as a prominent player in the pharmaceutical industry. The company has carved out a niche as a leading Contract Development and Manufacturing Organization (CDMO). It offers a comprehensive range of pharmaceutical products and services.
Akums’ main promoter is the Akums Master Trust, which holds 40.79% of its equity. The company’s Managing Directors, Mr. Sanjeev Jain and Mr. Sandeep Jain, own 17.23% and 17.24% stakes, respectively. Under their leadership, Akums has experienced significant growth. It has also built a strong reputation for quality and innovation. Apart from them, there are other managerial promoters who have contributed to the company's success. They are

Sanjay Sinha
Matangi Gowrishankar
Nand Lal Kalra
Sunil Kumar Thakur
Kewal Kundanlal Handa
Satwinder Singh

Akum’s diverse portfolio allows it to cater to a wide array of healthcare needs and market demands. Its expertise spans various dosage forms, including oral solids, injectables, cosmetics and nutraceuticals. The company’s registered office is located at LSC Saraswati Vihar, Delhi. Meanwhile, its registrars are based in Vikhroli, Mumbai.
Akums’ success is underpinned by its commitment to providing customised solutions that meet global standards. The company is renowned for its high-quality, safe, and effective formulations. Its manufacturing facilities and expertise have positioned it as a preferred partner for many in the industry.
It is not explicitly labelled as the top stock in its sector. However, Akums’ rapid growth and market presence reflect its importance in the pharmaceutical manufacturing landscape. The company’s focus on innovation and quality has enabled it to stay competitive in a rapidly evolving industry. As Akums continues to expand its reach, it remains dedicated to its mission of providing quality products and services.

How Akums is Revolutionising Contract Manufacturing in Pharma

Akums Drugs and Pharmaceuticals Ltd. is making major strides in the pharmaceutical industry. Founded in 2004 by the Jain brothers, Akums has grown to become India’s largest contract research and manufacturing services (CRAMS) company. This growth is driven by their commitment to quality and innovation.
Akums provides a range of services that cover the entire spectrum of pharmaceutical manufacturing. These services include formulation development, stability studies, regulatory approvals, packaging, and market launch. By offering such a broad array of services, Akums ensures that their clients can rely on them for all their manufacturing needs. This integrated approach simplifies the process for clients. It also ensures consistency and quality across all stages of production.
One of the key factors behind Akums’ success is its state-of-the-art manufacturing facilities. They operate over 15 advanced manufacturing units that are equipped with the latest technology. These facilities are capable of producing a wide range of dosage forms. This includes tablets, capsules, liquid orals, injectables, and more. The company’s commitment to maintaining high standards is evident in its numerous certifications, including WHO-GMP, ISO 9001, and ISO 14001.
Innovation is at the heart of Akums’ operations. The company invests heavily in research and development to stay ahead of industry trends. This focus on innovation has led to the development of new drug formulations and delivery systems. For instance, Akums recently received approval from the Drug Controller General of India (DCGI) to launch an antidiabetic drug called Lobeglitazone. This drug offers several advantages, including a higher safety profile. It also offers greater effectiveness at lower dosages.
Akums has also formed strategic partnerships with various companies. This is to expand their capabilities and market reach. In 2019, they received a significant investment from Quadria Capital, a healthcare-focused private equity firm. This partnership has enabled Akums to further enhance their manufacturing capabilities. It has also helped the company explore new growth opportunities. Additionally, Akums has collaborated with several multinational companies. This is to manufacture a diverse range of products, including pharmaceuticals, cosmetics, and more.
Sustainability is another area where Akums is making a difference. The company is committed to reducing its environmental footprint through various initiatives. These include the use of renewable energy sources and water conservation efforts. As a result, Akums contribute to environmental protection. It also ensures long-term operational efficiency and cost savings.
Looking ahead, Akums aims to continue its growth trajectory by expanding its market share and revenue. The company plans to increase its revenue to around ₹10,000 crore and capture a 20% market share in the next few years. To achieve these goals, Akums will focus on enhancing its service offerings and leveraging its partnerships. The company also plans to venture into new areas, such as biosimilars and vaccines, which present significant growth opportunities.
Overall, Akums Drugs and Pharmaceuticals Ltd. is revolutionising contract manufacturing in the pharmaceutical industry. The company achieves this through its comprehensive service offerings and quality. As the company continues to grow, it is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.